Related Experiment Video
Updated: Apr 20, 2026

Laser Capture Microdissection of Mouse Embryonic Cartilage and Bone for Gene Expression Analysis
Published on: December 18, 2019
Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating
Zi-Qiang Zhou1, Sara Ota1, Chuxia Deng2
1Shriners Hospitals for Children, 3101 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Abstract:
Fibroblast growth factor receptor 3 (FGFR3) plays a critical role in the control of endochondral ossification, and bone growth and mutations that cause hyperactivation of FGFR3 are responsible for a collection of developmental disorders that feature poor endochondral bone growth. FGFR3 is expressed in proliferating chondrocytes of the cartilaginous growth plate but also in chondrocytes that have exited the cell cycle and entered the prehypertrophic phase of chondrocyte differentiation. Achondroplasia disorders feature defects in chondrocyte proliferation and differentiation, and the defects in differentiation have generally been considered to be a secondary manifestation of altered proliferation. By initiating a mutant activated knockin allele of FGFR3 (FGFR3K650E) that causes Thanatophoric Dysplasia Type II (TDII) specifically in prehypertrophic chondrocytes, we show that mutant FGFR3 induces a differentiation block at this stage independent of any changes in proliferation. The differentiation block coincided with persistent expression of SOX9, the master regulator of chondrogenesis, and reducing SOX9 dosage allowed chondrocyte differentiation to proceed and significantly improved endochondral bone growth in TDII. These findings suggest that a proliferation-independent and SOX9-dependent differentiation block is a key driving mechanism responsible for poor endochondral bone growth in achondroplasia disorders caused by mutations in FGFR3.
Insights
Mutant fibroblast growth factor receptor 3 (FGFR3) causes a differentiation block in chondrocytes, hindering bone growth. Reducing SOX9 levels rescues this block and improves endochondral ossification in developmental disorders.
Area of Science:
- Skeletal biology
- Developmental genetics
- Molecular endocrinology
Background:
- Fibroblast growth factor receptor 3 (FGFR3) is crucial for endochondral ossification and bone growth.
- Mutations leading to FGFR3 hyperactivation cause developmental disorders with impaired bone growth.
- FGFR3 is expressed in growth plate chondrocytes, including those in the prehypertrophic phase.
Purpose of the Study:
- To investigate the role of FGFR3 in chondrocyte differentiation independent of proliferation.
- To determine the mechanism by which mutant FGFR3 impairs endochondral bone growth.
- To identify potential therapeutic targets for FGFR3-associated skeletal dysplasias.
Main Methods:
- Generated a knockin mouse model with a constitutively active FGFR3 allele (FGFR3K650E) specifically in prehypertrophic chondrocytes.
- Analyzed chondrocyte proliferation, differentiation, and gene expression.
- Assessed endochondral bone growth and SOX9 (master regulator of chondrogenesis) expression levels.
- Manipulated SOX9 dosage to evaluate its impact on differentiation and bone growth.
Main Results:
- Mutant FGFR3 induced a differentiation block in prehypertrophic chondrocytes, independent of proliferation changes.
- This block was associated with persistent SOX9 expression.
- Reducing SOX9 dosage rescued the differentiation defect and significantly improved endochondral bone growth in the FGFR3K650E model.
Conclusions:
- A proliferation-independent, SOX9-dependent differentiation block is a key mechanism in FGFR3-associated skeletal disorders.
- Targeting SOX9 may offer a therapeutic strategy for improving bone growth in conditions like Thanatophoric Dysplasia Type II.
- These findings refine our understanding of FGFR3's role in skeletal development and disease.
Related Concept Videos
Bone Formation by Endochondral Ossification
Pleiotropy
TGF - β Signaling Pathway
Hedgehog Signaling Pathway
Growth of Cartilage and Bone Tissue

